EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, MESO: Mesoblast Ltd ADR

12 Nov 25 13:13
LAST:

15.51

CHANGE:
 0.02		OPEN:
15.84		HIGH:
15.84		ASK:
6.92		VOLUME:
40.7K
CHG(%):
0.13		PREV:
15.53		LOW:
15.33		BID:
4.19		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
12 Nov 2515.8415.8415.3315.5140.7K
11 Nov 2515.2215.5715.1915.53180.4K
10 Nov 2515.0315.3415.0215.21141.5K
07 Nov 2514.5714.6214.1014.61268.8K
06 Nov 2515.2015.2914.8014.93227.9K
05 Nov 2515.5315.8315.4615.54135.9K
04 Nov 2515.6715.9315.5815.59117.8K
03 Nov 2516.3616.3615.7116.11281.3K
31 Oct 2516.5016.9116.3816.66146.2K
30 Oct 2516.3616.5216.1016.4383.5K

COMPANY PROFILE

Name:Mesoblast Ltd ADR
About:Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Sector:Healthcare
Industry:Biotechnology
Address:55 Collins Street, Melbourne, VIC, Australia, 3000
Website:https://www.mesoblast.com
CUSIP:590717104
CIK:0001345099
ISIN:US5907171046
FIGI:BBG000QD6LZ1
LEI:529900J5ALF3JG921927

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:15.162.3%
MA10:15.610.7%
MA20:16.415.8%
MA50:16.456.1%
MA100:15.162.3%
MA200:14.139.8%
STO9:39.13
STO14:35.02
RSI14:30.47 
WPR14:-59.09
MTM14:-1.30
ROC14:-0.08 
ATR:0.55 
Week High:15.842.1%
Week Low:14.1010.0%
Month High:18.9422.1%
Month Low:14.109.8%
Year High:22.0041.8%
Year Low:9.6161.4%
Volatility:37.57 

RECENT SPLITS

Date Ratio
10 Jan 20241-2